Issue link: http://deals.uberflip.com/i/1323418
LEADING BIOSTATISTICS CONSULTING FIRM #59893 BUSINESS HIGHLIGHTS The Company is a biosta s cs consul ng firm specializing in clinical SAS programming and sta s cal support to the pharmaceu cal industry. The Company is a niche firm specializing in sta s cal support during the final stage of new drug research and development. Experts from the Company analyze clinical trial data and report them per industry standards to assist in winning FDA approvals for their clients. When clinical trial raw data becomes available to the Company, hundreds of millions of dollars in R&D have typically already been spent; as a result, it is cri cal to get this valuable data analyzed and reported with speed and a high degree of accuracy so the high-cost clinical trials can be successfully completed. The Company operates virtually - employees and contractors operate either from a home office or from a client's loca on. Its core staff totals 30 full- me analysts and contractor labor when necessary. Ahmad Behja Senior Vice President - M&A E: abehja @genera onal.com D. 203-716-1185 M. 203-945-8919 INVESTMENT BANK OF THE YEAR 2016 - 2017 - 2018 DISCLAIMER: All informa on contained in this document has been provided by the subject company to Genera onal Equity and while believed to be correct has not been verified. Accordingly, Genera onal Equity makes no representa ons or warran es as to the accuracy and truthfulness of such informa on. The recipient hereof acknowledges that Genera onal Equity shall not be liable for any loss or injury suffered by said recipient in any way connected to the delivery by Genera- onal Equity of this document. At all mes Genera onal Equity and/or its affiliate network members are agents for the seller and not for the buyer. Genera onal Equity's fees are paid by the seller. REVENUE / EBITDA 2019 Revenue INVESTMENT APPEAL a. Strong Customer Rela onships: Management is proud of the many loyal customer rela onships built over the Company's history and believes customer rela onships will successfully transi on to new ownership. The Company has strong es to clients due to its reputa on for top analy cal services and excellent customer service and this commitment is represented in the strong reten on rate of accounts. b. Proprietary Exper se: In addi on to the principal's extensive experience in the industry, many of the Company's key employees and managers have long histories in the industry. This wealth of experience and exper se provides the Company with a significant intangible value and advantage over many compe tors. c. Management Will Remain Through Transi on: To facilitate a successful and orderly transi on, the current owner is willing to remain with the Company during a transi on period. d. Growth Opportuni es: Management cites several opportuni es to accelerate growth trends over the next few years by increasing sales and marke ng, and expanding geographically. The resultant revenue and profitability derived from these ventures has not been included in the projec ons contained herein. e. Industry Growth: Annual worldwide revenue from pharmaceu cal manufacturing is more than $1 trillion and is expected to grow to about $1.4 trillion for 2020, according to market intelligence firm IMS Health. Worldwide spending on medicines is increasing due to economic growth in developing na ons and the rising cost of specialty drugs. Genera onal Equity 125 Park Avenue, 25th FL New York, NY 10017 T. 212-381-7650 F. 203-738-1100 $914K $1.0M $5.26M $5.79M 2020 Revenue (PROJ) 2020 EBITDA (PROJ) 2019 EBITDA SIGN NDA ► CLIENT ACCOUNTS 2019 30 2019 Repeat Business 50%+ 87% STAFF OVERVIEW Full Time 30 Part Time (as needed) 5-6 SAMPLE OF CLIENT TARGETS REVENUE SOURCES Individual Consul ng 90% In-house Projects 10% CUSTOMER MARKETS Biotechnology R&D 100%